JSJohn W. Snelgrove

John W. Snelgrove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John W. Snelgrove has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 18 May 2026
      • p. 103396

    Rethinking Preeclampsia: How Placental Growth Factor (PlGF) Is Transforming Diagnosis and Management.

    by John W Snelgrove

    Preeclampsia is a severe pregnancy complication affecting pregnant people, their babies, and families. It remains a leading global cause of maternal and fetal morbidity and mortality. Our understanding of this disease continues to evolve, with opportunities for improved preeclampsia prediction, diagnosis, and management. This review outlines how placental growth factor (PlGF) could help clinicians better predict, diagnose, and ultimately manage preeclampsia and its complications. The material was originally presented at the Cannell Lecture in Toronto on 29 November 2024. The Cannell Lecture is hosted annually by the Society of Obstetricians & Gynaecologists of Canada and the University of Toronto in honour of Dr. Doug Cannell, who was Chair of the Department of Obstetrics & Gynaecology from 1950-1965.

  • Open Access

    SARS-CoV-2 Infection and Rates of Neonatal Congenital Anomalies

    by John W. Snelgrove, Rinku Sutradhar, Nancy N. Baxter, Karl Everett, Stephanie C. Lapinsky, Douglas M. Campbell, Mark H. Yudin, Howard Berger, Eliane M. Shore, Andrea N. Simpson

    Importance: There is conflicting evidence for associations between maternal SARS-CoV-2 infection and neonatal congenital anomalies. Population-based studies evaluating confirmed maternal infection during pregnancy and at specific gestational time periods are needed. Objective: To evaluate associations between laboratory-confirmed maternal SARS-CoV-2 infection in pregnancy and neonatal congenital anomalies, overall during pregnancy and by specific trimester of exposure. Design, Setting, and Participants: This population-based, matched cohort study of live births with maternal SARS-CoV-2 infection in pregnancy matched 1:4 to live births without maternal infection in Ontario, Canada, was conducted from December 14, 2020, to December 31, 2021. Matching was performed on maternal age, delivery date, gestational age at birth, neonatal sex, and prepregnancy diabetes. Analyses were conducted from May to August 2025. Exposure: Maternal SARS-CoV-2 infection in pregnancy confirmed by positive real-time polymerase chain reaction (RT-PCR) test. Pregnancies with no positive RT-PCR test were considered SARS-CoV-2 negative. Main Outcomes and Measures: The primary outcome was any neonatal congenital anomaly. The secondary outcome was any neonatal cardiac anomaly. Crude incidence rates of congenital anomalies per 1000 live births by maternal SARS-CoV-2 infection status with 95% CI were determined with a Poisson distribution for the study sample overall, and by each trimester of exposure. Results: A total of 5049 live births with corresponding maternal SARS-CoV-2 infection in pregnancy (mean [SD] maternal age, 31.0 [4.9] years) were matched 1:4 to 20 196 live births without maternal infection (mean [SD] maternal age, 31.1 [4.7] years). Compared with patients without infection, those with infection were more likely to be immigrants and to have high levels of material deprivation and were less likely to receive COVID-19 vaccination and live in rural areas. The crude incidence rate of any congenital anomaly was 32.5 anomalies per 1000 live births (95% CI, 27.9-37.9 anomalies per 1000 live births) with maternal SARS-CoV-2 infection and 31.1 anomalies per 1000 live births (95% CI, 28.8-33.6 anomalies per 1000 live births) without maternal SARS-CoV-2 infection (unadjusted rate ratio, 1.04; 95% CI, 0.87-1.24; P = .65). Multivariable logistic regression adjusting for maternal socioeconomic variables and prepregnancy COVID-19 vaccination did not alter these findings. Infection separately by trimester was not statistically significantly associated with the outcome. There were no statistically significant associations between maternal SARS-CoV-2 infection and cardiac anomalies in pregnancy overall or by trimester. Conclusions and Relevance: In this Ontario population-based study of 5049 live births with maternal SARS-CoV-2 infection matched to 20 196 live births without maternal infection, there was no association between laboratory-confirmed maternal SARS-CoV-2 infection and neonatal congenital anomalies in pregnancy overall, or by trimester of infection. These findings may provide reassurance to pregnant patients and their health care professionals, although further studies evaluating first trimester infection and risks of specific anomalies are warranted.

  • Antenatal corticosteroids for short cervix: When is it indicated – a cohort study

    by Lennart Van der Veeken, Diya Ahmad, Simonne Holubeshen, Kellie E. Murphy, John W. Snelgrove

  • Open Access

    Patterns of Aspirin Non-Use by Preeclampsia Risk Factors in High-Risk Pregnancies: A Retrospective Cohort Study

    by Leonet B. Reid, Kelsey McLaughlin, Hilary K. Brown, Valeria E. Rac, John C. Kingdom, John W. Snelgrove


  • Mid-pregnancy circulating placental growth factor (PlGF) and obstetrical outcomes following nonovulatory and ovulatory frozen embryo transfer cycles

    by Trish Dinh, Nichole Sanchez Diaz, Kelsey McLaughlin, John C. Kingdom, Ellen M. Greenblatt, Sascha Drewlo, John W. Snelgrove

    Purpose We compared serum placental growth factor (PlGF) concentration in pregnancies from ovulatory vs. non-ovulatory FET cycles and evaluated associations with obstetrical and neonatal outcomes. Methods We conducted a secondary analysis of a prospective single-center screening study at a large urban center in Canada where PlGF was performed between April 2020 and December 2022. Baseline characteristics were compared between FET ovulatory cycle and non-ovulatory cycle groups. We compared PlGF concentration in unadjusted and adjusted analyses using multivariable linear regression. Secondary outcomes were compared using chi square and Fisher exact tests for categorical variables and Wilcoxon rank sum tests for continuous variables. Results We identified 340 patients, 246 (72.4%) in the non-ovulatory group and 94 (27.7%) in the ovulatory group. The median gestational age (IQR) at PlGF testing was 27.9 weeks (26.6–28.3) in the non-ovulatory group and 27.7 weeks (25.6–28.1) in the ovulatory group (p = 0.07). Univariable analysis comparing the difference in PlGF showed no association between groups [β − 51.7 (95% CI − 43.7–384.1), p = 0.44]. After adjusting for maternal age, race, parity, pre-pregnancy BMI, gestational diabetes, gestational age of PlGF test, donor egg cycle, and maternal and previous obstetrical comorbidities, the difference in PlGF concentration remained non-significant. Obstetrical and neonatal outcomes were similar between groups. Conclusion Our findings indicate no significant difference in either mid-pregnancy circulating PlGF concentration or obstetrical outcomes comparing successful FETs in ovulatory vs. non-ovulatory cycles. Larger-scale prospective research should be prioritized to further elucidate the role of PlGF in predicting the potential risk of adverse pregnancy outcomes.

  • Health Care Utilization of Children Born to Women With and Without Inflammatory Bowel Disease in the First 5 Years of Life: A Population-Cohort Study

    by Parul Tandon, Vivian Huang, Denice S. Feig, Refik Saskin, Cynthia Maxwell, Deshayne B. Fell, Cynthia H. Seow, John W. Snelgrove, Geoffrey C. Nguyen

    INTRODUCTION: Children born to women with inflammatory bowel disease (IBD) may have increased health care utilization in early life due to genetic susceptibilities and exposure to inflammation in utero, although this has not been robustly evaluated. We aimed to characterize health care use between these groups. METHODS: We accessed province-wide health administrative databases to identify children born to women with and without IBD between 2002 and 2019. Differences in hospitalizations, emergency department visits, ambulatory visits, and endoscopy visits in the first 5 years of life were characterized. We further assessed differences in mental health-related health care utilization between groups. Multivariable negative binomial regression was performed to calculate adjusted incidence rate ratios (IRRs) with 95% confidence intervals (CIs). RESULTS: We included 17,447 and 1,832,334 children born to women with and without IBD, respectively. Compared with those born to women without IBD, children born to women with IBD appeared to have an increased rate of all-cause hospitalizations (IRR 1.06, 95% CI 1.03–1.10), all-cause emergency department visits (IRR 1.08, 95% CI 1.05–1.10), ambulatory visits (IRR 1.06, 95% CI 1.05–1.07), and endoscopic visits (IRR 2.14, 95% CI 1.70–2.69). Children born to women with IBD also seemed to have increased mental health-related ambulatory visits (IRR 1.93, 95% CI 1.01–3.76), with the most common reasons coded for these visits being neurodevelopmental/behavioral and developmental delay concerns. DISCUSSION: Children born to women with IBD may have increased health care utilization compared with those born to women without IBD.


  • Neurological care and outcomes in a cohort of Canadian pregnant patients with epilepsy

    by Julien Hébert, Sharon Ng, Yajur Iyengar, Sabrina S.-W. Chan, John W. Snelgrove, Esther Bui


  • Maternal Placental Growth Factor (PlGF) levels, sonographic placental parameters, and outcomes of IVF pregnancies with and without embryo trophectoderm biopsy

    by John W. Snelgrove, Rachel Lee, Yaanu Jeyakumar, Ellen M. Greenblatt, John C. Kingdom, Rhonda Zwingerman, Kelsey McLaughlin

    PURPOSE In vitro fertilization (IVF) is associated with abnormal trophoblast invasion and resultant decreased levels of circulating placental biomarkers such as placental growth factor (PlGF). Our objective was to evaluate maternal serum levels of second/third trimester PlGF, sonographic placental parameters, and clinical outcomes among IVF frozen embryo transfer (FET) pregnancies with and without embryo trophectoderm biopsy. METHODS This was a retrospective study of pregnant patients who conceived using a single frozen embryo transfer (FET) and gave birth between 30 January 2018 and 31 May 2021. We compared PlGF levels, sonographic placental parameters, and clinical outcomes between FET with biopsy and FET without biopsy groups. RESULTS The median PlGF level was 614.5 pg/mL (IQR 406–1020) for FET pregnancies with biopsy, and 717.0 pg/mL (IQR 552–1215) for FET pregnancies without biopsy. The adjusted mean difference was 190.9 pg/mL lower in the FET biopsy group (95% CI, –410.6, 28.8; p = 0.088). There were no statistically significant differences in placental parameters or clinical pregnancy outcomes. CONCLUSION This exploratory study demonstrated a possible trend toward lower maternal serum PlGF in the pregnancies conceived with FET using a biopsied embryo. Further investigation is warranted into the potential placental health effects of trophectoderm biopsy.


  • Recent Immigrants With Inflammatory Bowel Disease Have Significant Healthcare Utilization From Preconception to Postpartum: A Population Cohort Study

    by Parul Tandon, Vivian Huang, Denice S. Feig, Refik Saskin, Cynthia Maxwell, Yiding Gao, Deshayne B. Fell, Cynthia H. Seow, John W. Snelgrove, Geoffrey C. Nguyen

    INTRODUCTION: Immigrants with inflammatory bowel disease (IBD) may have increased healthcare utilization during pregnancy compared with non-immigrants, although this remains to be confirmed. We aimed to characterize this between these groups. METHODS: We accessed administrative databases to identify women (aged 18–55 years) with IBD with a singleton pregnancy between 2003 and 2018. Immigration status was defined as recent (<5 years of the date of conception), remote (≥5 years since the date of conception), and none. Differences in ambulatory, emergency department, hospitalization, endoscopic, and prenatal visits during 12 months preconception, pregnancy, and 12 months postpartum were characterized. Region of immigration origin was ascertained. Multivariable negative binomial regression was performed for adjusted incidence rate ratios (aIRRs) with 95% confidence intervals (CIs). RESULTS: A total of 8,880 pregnancies were included, 8,304 in non-immigrants, 96 in recent immigrants, 480 in remote immigrants. Compared with non-immigrants, recent immigrants had the highest rates of IBD-specific ambulatory visits during preconception (aIRR 3.06, 95% CI 1.93–4.85), pregnancy (aIRR 2.15, 95% CI 1.35–3.42), and postpartum (aIRR 2.21, 1.37–3.57) and the highest rates of endoscopy visits during preconception (aIRR 2.69, 95% CI 1.64–4.41) and postpartum (aIRR 2.01, 95% CI 1.09–3.70). There were no differences in emergency department and hospitalization visits between groups, although those arriving from the Americas were the most likely to be hospitalized for any reason. All immigrants with IBD were less likely to have a first trimester prenatal visit. DISCUSSION: Recent immigrants were more likely to have IBD-specific ambulatory care but less likely to receive adequate prenatal care during pregnancy.